Hua LH - Search Results

1

Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM. Graves JS, et al. Among authors: hua lh. Lancet Neurol. 2023 Jan;22(1):66-77. doi: 10.1016/S1474-4422(22)00184-3. Epub 2022 Oct 7. Lancet Neurol. 2023. PMID: 36216015 Review.

2

Considerations in the development of generic disease therapies for multiple sclerosis.

Hua LH, Cohen JA. Hua LH, et al. Neurol Clin Pract. 2016 Aug;6(4):369-376. doi: 10.1212/CPJ.0000000000000267. Neurol Clin Pract. 2016. PMID: 27574572 Free PMC article. Review.

3

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.

Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG. Hua LH, et al. Mult Scler. 2019 Apr;25(5):699-708. doi: 10.1177/1352458518765656. Epub 2018 Mar 20. Mult Scler. 2019. PMID: 29557704

4

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.

5

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Conway DS, Hersh CM, Harris HC, Hua LH. Conway DS, et al. Among authors: hua lh. Mult Scler J Exp Transl Clin. 2020 Jan 27;6(1):2055217320902488. doi: 10.1177/2055217320902488. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32064117 Free PMC article.

6

Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.

Obeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Obeidat AZ, et al. Among authors: hua lh. Neurology. 2020 Mar 17;94(11):495-500. doi: 10.1212/WNL.0000000000009096. Epub 2020 Feb 27. Neurology. 2020. PMID: 32107321 Free PMC article.

7

Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy.

Goldschmidt CH, Hua LH. Goldschmidt CH, et al. Among authors: hua lh. Degener Neurol Neuromuscul Dis. 2020 Jun 26;10:29-38. doi: 10.2147/DNND.S224912. eCollection 2020. Degener Neurol Neuromuscul Dis. 2020. PMID: 32617031 Free PMC article. Review.

8

Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Hua LH, Hersh CM, Tian F, Mowry EM, Fitzgerald KC. Hua LH, et al. Mult Scler Relat Disord. 2021 Jan;47:102637. doi: 10.1016/j.msard.2020.102637. Epub 2020 Nov 23. Mult Scler Relat Disord. 2021. PMID: 33276238 Free PMC article.

9

Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.

Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Hua LH, et al. Neurol Clin Pract. 2021 Aug;11(4):352-357. doi: 10.1212/CPJ.0000000000001040. Neurol Clin Pract. 2021. PMID: 34484933 Free PMC article.

10

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.

Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D. Okuda DT, et al. Among authors: hua lh. Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. Ann Neurol. 2023. PMID: 36401339 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page